ESMO 2019 - Results from #80

Viewing 81-100 of 138 articles

ESMO 2019: Pre-operative Ipilimumab and Nivolumab in Locoregionally Advanced, Stage III, Urothelial Cancer (NABUCCO) 

ESMO 2019: A First-in-Human Phase I/II Trial of the Oral HIF-2a Inhibitor PT2977 in Patients with Advanced Renal Cell Carcinoma

ESMO 2019: Central, Prospective Detection of Homologous Recombination Repair Gene Mutations in Tumor Tissue from >4000 Men with mCRPC Screened for the PROfound Study

ESMO 2019: Preliminary Results from the TRITON2 Study of Rucaparib in Patients with DNA Damage Repair-deficient mCRPC: Updated Analyses

ESMO 2019: Invited Discussant: (LBA50, 845PD, 846PD and 847PD) Genitourinary Tumors, Prostate

ESMO 2019: Invited Discussant: (LBA50, 845PD, 846PD and 847PD)Phase 2 Study GALAHAD, CDK12-altered Prostate Cancer, Preliminary results from the TRITON2 study, and HRRm in Tumor Tissue from men with mCRPC Screened for the PROfound Study

ESMO 2019: CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, PARP and PD1 Inhibitors

ESMO 2019: Pre-Specified Interim Analysis of GALAHAD: A Phase 2 Study of Niraparib in Patients with mCRPC and Biallelic DNA-Repair Gene Defects

ESMO 2019: CCTG IND 232 - Phase II Study of Durvalumab with or without Tremelimumab in Patients with mCRPC

ESMO 2019: GALAHAD - A Phase 2 Study of Niraparib in Patients with mCRPC and Biallelic DNA-Repair Gene Defects, A Pre-Specified Interim Analysis

ESMO 2019: CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, PARP inhibitors, and PD1 inhibitors

ESMO 2019: Primary Efficacy Analysis from the SORCE trial (RE05): Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse

ESMO 2019: Tailored Immunotherapy Approach with Nivolumab for Advanced Renal Cell Carcinoma (TITAN-RCC)

ESMO 2019: Invited Discussant - Review of SORCE and TITAN-RCC

ESMO 2019: Invited Discussant: Review of ENTRATA for Renal Cell Carcinoma and TROPHY-U-01 for Metastatic Urothelial Cancer

ESMO 2019: Invited Discussant: Results from the SORCE Trial and Nivolumab in Advanced Renal Cell Carcinoma, the TITAN-RCC Trial

ESMO 2019: Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse, Results from the SORCE Trial

ESMO 2019: A Tailored ImmunoTherapy Approach with Nivolumab in advanced Renal Cell Carcinoma in the TITAN-RCC Trial

ESMO 2019: Invited Discussant: The International Germ Cell Cancer Collaborative Group Update

ESMO 2019: Invited Discussant for EV-103: Initial Results of Enfortumab Vedotin plus Pembro and of BISCAY, an Adaptive, Biomarker Directed Platform study in Metastatic Urothelial Cancer

1
2
3
4
5
6
7